Table 1 Comparison of baseline data between warfarin and rivaroxaban groups

Age (years)

59 (15.62)

58.25 (17.73)

0.86

Male

34 (97.14%)

24 (85.71%)

0.16

BMI (kg/m²)

28.1 (4.04)

27.59 (5.88)

0.69

BSA (m²)

1.91 (0.16)

1.87 (0.25)

0.51

Diabetes mellitus

16 (45.71%)

12 (42.86%)

0.82

Hypertension

19 (54.29%)

13 (46.43%)

0.54

Atrial fibrillation

2 (5.71%)

1 (3.57%)

˃ 0.99

Myocardial infarction

25 (71.43%)

16 (57.14%)

0.24

Hemoglobin (g/dl)

14.1 (1.91)

13.4 (2.25)

0.19

Creatinine clearance (ml/min)

80.6 (38.66)

92.28 (32.37)

0.21

ALT (U/L)

21 (17-34)

31 (18-43)

0.10

ALP (U/L)

90 (70-108)

86 (72-115)

0.97

Aspirin

20 (57.14%)

19 (67.86%)

0.38

P2Y12 inhibitors (clopidogrel)

21 (60%)

13 (46.43%)

0.24

Ejection fraction (%)

27.29 (7.8)

26.43 (8.15)

0.67

LVT surface area (cm²)

1.77 (0.66-2.21)

1.75 (0.7-3.49)

0.3

Moderate MR

5 (14.3%)

7 (25%)

0.28

Moderate TR

3 (8.6%)

5 (17.9%)

0.45

Dilated LV

9 (25.71%)

14 (50%)

0.047

INR base

1.2 (1.1-2.2)

1.2 (1.1-1.6)

0.92